Announcements Trials

Browse Landscape

Phase

Phase 2 40 Phase 3 20 Phase 1/2 10 Phase 1 10 Phase NA 2 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Cisplatin 22 Magnetic Resonance Spectroscopy 18 Gemcitabine 14 Carboplatin 14 pembrolizumab 13 Specimen Handling 13 Paclitaxel 13 Bevacizumab 11 Radiotherapy 10 Nivolumab 10 atezolizumab 8 Radiation 8 Platinum 8 Doxorubicin 8 Docetaxel 8 1,2-diaminocyclohexaneplatinum II citrate 8 Pemetrexed 7 Drug Therapy 7 Dexamethasone 7 Temozolomide 6 Ipilimumab 6 Surgical Procedures, Operative 5 Rituximab 5 Radiotherapy, Intensity-Modulated 5 Prednisone 5 Cytarabine 5 Cyclophosphamide 5 Biopsy 5 130-nm albumin-bound paclitaxel 5 venetoclax 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Trastuzumab × 90 days × Clear all

NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡